Kynurenine-dependent redox signaling at the interface between innate and adaptive immunity
先天免疫和适应性免疫之间界面的犬尿氨酸依赖性氧化还原信号传导
基本信息
- 批准号:10749210
- 负责人:
- 金额:$ 56.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-19 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAllyAnti-Inflammatory AgentsAntigen-Presenting CellsAryl Hydrocarbon ReceptorAttenuatedAutoimmune DiseasesAutoimmunityBiological AssayCellsChronicCysteineCytoprotectionDataDendritic CellsDevelopmentEndotoxemiaEndotoxinsEnergy MetabolismExposure toFosteringFoundationsGenerationsGenesGenetic TranscriptionGoalsGraft RejectionHealthHepatocyteHumanImmuneImmune ToleranceImmune responseInflammasomeInflammationInflammatoryInflammatory ResponseInterventionIsotopesKineticsKnowledgeKynurenineLabelLeukocytesLifeLigandsLinkLiverMacrophageMalignant NeoplasmsMediatingMediatorMetabolicMetabolismMissionMitochondriaModelingMolecularMusMyelogenousMyeloid Cell ActivationNatural ImmunityOrgan TransplantationOutcomeOxidation-ReductionPathway interactionsPhenotypePublic HealthPublishingReactionReceptor SignalingRegulationRegulatory T-LymphocyteReportingResearchResistanceRespirationRoleSecondary toSepsisSignal PathwaySignal TransductionSolidSulfhydryl CompoundsSupplementationT cell differentiationT-LymphocyteTLR4 geneTestingToll-like receptorsTryptophanTryptophan Metabolism PathwayTryptophanaseUnited States National Institutes of HealthUp-RegulationWorkadaptive immunityallograft rejectionchemical synthesisdesigndisabilityextracellularimmune activationimmunoregulationin vivoindoleamineinsightknockout animalmetabolomicsnovelnovel therapeuticspharmacologicpolarized cellprogramsresponsesystemic inflammatory responseuptake
项目摘要
The kynurenine pathway catabolizes over 95% of all tryptophan primarily through the actions of
tryptophan 2,3-dioxygenase 2 (TDO2) in hepatocytes and indoleamine 2,3-dioxygenese 1 (IDO1) in myeloid
leukocytes. Increased kynurenine synthesis in dendritic cells (DC) secondary to IDO1 upregulation is strongly
linked with the generation of a tolerogenic phenotype by promoting anti-inflammatory signaling, regulatory T cell
(Treg) polarization and immune tolerance, an attenuated inflammatory response instigated by immune cells that
are repeatedly exposed to TLR ligands. However, while the pathophysiologic relevance of this pathway is well-
established, the mechanism behind the immunomodulatory effects of kynurenine remain poorly defined. Using
semi-targeted metabolomic approaches, we recently published that systemic increases in kynurenine levels
secondary to either exogenous supplementation or chronic inflammation are associated with the formation of the
novel cysteine-reactive kynurenine-derived electrophile Kyn-CKA. Kyn-CKA promotes Nrf2-depedent signaling,
inhibits TLR4-dependent NF-κB pathways and attenuates inflammatory responses in endotoxin-challenged mice
in a redox-dependent manner. In addition, Kyn-CKA engages AhR signaling with 20-fold higher potency than its
kynurenine precursor, suggesting a potential pro-tolerogenic role in DC and T-cells. Specifically designed state-
of-the-art LC-MS/MS assays will enable the quantification of Kyn-CKA in the context of other kynurenine pathway
metabolites in activated and non-activated myeloid leukocytes, as well as the elucidation of rate-limiting cellular
uptake and export mechanisms. Primary macrophages, dendritic, and T cells derived from pathway-specific
knock-out animals will be harnessed in conjunction with novel bio-orthogonal labeling strategies and isotope-
tracing metabolic flux analyses to define the mechanistic basis of the anti-inflammatory actions of Kyn-CKA both
in terms of the modulation of specific signaling pathways and its effects on inflammation-elicited changes in
energy metabolism. The ability of Kyn-CKA to promote tolerogenic responses will be established by assessing
its effect on the maturation and activation of conventional DC subpopulations, its impact on T cell polarization,
and its ability to modulate endotoxin resistance and tolerance in vivo. Mice expressing or lacking critical
mediators of Kyn-CKA formation and action in cell-specific compartments will be used to obtain mechanistic
insights in vivo. In summary, the Research Plan addresses a hitherto unappreciated redox-dependent
component of the immunomodulatory actions of the kynurenine pathway, mediated by the formation of
electrophilic Kyn-CKA. If successful, our work will enable the potential development of novel Kyn-CKA based
pharmacological interventions for dysregulated immune responses such as chronic inflammation, autoimmune
diseases, cancer, and allograft rejection.
犬尿氨酸途径主要通过以下作用分解代谢超过95%的所有色氨酸:
肝细胞中的色氨酸2,3-双加氧酶2(TDO 2)和骨髓中的吲哚胺2,3-双加氧酶1(IDO 1)
白细胞树突状细胞(DC)中继发于IDO 1上调的犬尿氨酸合成增加强烈地抑制了IDO 1的表达。
与通过促进抗炎信号传导产生致耐受性表型相关,调节性T细胞
(Treg)极化和免疫耐受,由免疫细胞引起的减弱的炎症反应,
反复暴露于TLR配体。然而,虽然这一途径的病理生理相关性很好-
尽管犬尿氨酸的免疫调节作用已经建立,但犬尿氨酸的免疫调节作用背后的机制仍然不清楚。使用
半靶向代谢组学方法,我们最近发表了犬尿氨酸水平的全身性增加,
继发于外源性补充或慢性炎症与形成的
新型半胱氨酸反应性犬尿氨酸衍生的亲电体Kyn-CKA。Kyn-CKA促进Nrf 2依赖性信号传导,
抑制TLR 4依赖的NF-κB通路并减轻内毒素攻击小鼠的炎症反应
以氧化还原依赖的方式。此外,Kyn-CKA参与AhR信号传导的效力比其高20倍。
犬尿氨酸前体,表明在DC和T细胞中的潜在促耐受性作用。特别设计的国家-
最先进的LC-MS/MS测定将能够在其他犬尿氨酸途径的背景下定量Kyn-CKA
活化和非活化髓系白细胞中的代谢物,以及阐明限速细胞
吸收和出口机制。原代巨噬细胞、树突状细胞和T细胞来源于通路特异性
基因敲除动物将与新的生物正交标记策略和同位素-
跟踪代谢通量分析,以确定Kyn-CKA抗炎作用的机制基础,
在特定信号通路的调节及其对炎症引起的变化的影响方面,
能量代谢将通过评估Kyn-CKA促进致耐受性应答的能力,
其对常规DC亚群的成熟和活化的作用,其对T细胞极化的影响,
以及其在体内调节内毒素抗性和耐受性的能力。小鼠表达或缺乏关键
Kyn-CKA形成的介质和细胞特异性隔室中的作用将用于获得机制
在体内的洞察力。总之,该研究计划解决了迄今未被重视的氧化还原依赖性
犬尿氨酸途径的免疫调节作用的组成部分,通过形成
亲电Kyn-CKA。如果成功,我们的工作将使潜在的开发新的Kyn-CKA为基础的
用于失调的免疫应答如慢性炎症、自身免疫
疾病、癌症和同种异体移植排斥。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dario A Vitturi其他文献
Role of Hemoglobin Beta93Cys as an Antioxidant in the Vascular Compartment: Implications for Vascular Homeostasis During Endotoxemia
- DOI:
10.1016/j.freeradbiomed.2010.10.423 - 发表时间:
2010-01-01 - 期刊:
- 影响因子:
- 作者:
Dario A Vitturi;Chiao-Wang Sun;Nadiezhda Cantu-Medellin;Victoria M Harper;Ning Peng;Yanying Dai;J Michael Wyss;Tim M Townes;Rakesh P Patel - 通讯作者:
Rakesh P Patel
The Effects of Red Blood Cell Storage Time on Nitric Oxide and Nitrite-dependent Signaling
- DOI:
10.1016/j.freeradbiomed.2010.10.053 - 发表时间:
2010-01-01 - 期刊:
- 影响因子:
- 作者:
Ryan Daniel Stapley;Dario A Vitturi;Cilina Rodriguez;Rakesh P Patel - 通讯作者:
Rakesh P Patel
Dario A Vitturi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dario A Vitturi', 18)}}的其他基金
Biological actions of endogenous Kynurenine-derived electrophiles
内源性犬尿氨酸衍生的亲电子试剂的生物学作用
- 批准号:
10537499 - 财政年份:2022
- 资助金额:
$ 56.43万 - 项目类别:
Anti-inflammatory actions of a novel hemin-induced electrophile in Sickle Cell Disease
新型血红素诱导的亲电子试剂在镰状细胞病中的抗炎作用
- 批准号:
10688690 - 财政年份:2022
- 资助金额:
$ 56.43万 - 项目类别:
Biological actions of endogenous Kynurenine-derived electrophiles
内源性犬尿氨酸衍生的亲电子试剂的生物学作用
- 批准号:
10724511 - 财政年份:2022
- 资助金额:
$ 56.43万 - 项目类别:
Anti-inflammatory actions of a novel hemin-induced electrophile in Sickle Cell Disease
新型血红素诱导的亲电子试剂在镰状细胞病中的抗炎作用
- 批准号:
10402907 - 财政年份:2021
- 资助金额:
$ 56.43万 - 项目类别:
Anti-inflammatory actions of a novel hemin-induced electrophile in Sickle Cell Disease
新型血红素诱导的亲电子试剂在镰状细胞病中的抗炎作用
- 批准号:
10211085 - 财政年份:2021
- 资助金额:
$ 56.43万 - 项目类别:
Protection against sickle cell disease nephropathy by nitrated fatty acids
硝化脂肪酸预防镰状细胞病肾病
- 批准号:
10405745 - 财政年份:2016
- 资助金额:
$ 56.43万 - 项目类别:
Protection against sickle cell disease nephropathy by nitrated fatty acids
硝化脂肪酸预防镰状细胞病肾病
- 批准号:
9164507 - 财政年份:2016
- 资助金额:
$ 56.43万 - 项目类别:
Protection against sickle cell disease nephropathy by nitrated fatty acids
硝化脂肪酸预防镰状细胞病肾病
- 批准号:
9320025 - 财政年份:2016
- 资助金额:
$ 56.43万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 56.43万 - 项目类别:
Research Grant














{{item.name}}会员




